Article Information
History
- December 6, 2021.
Article Versions
- Version 1 (August 22, 2021 - 00:32).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Daniel Junker1,
- Alex Dulovic1,
- Matthias Becker1,
- Teresa R. Wagner1,2,
- Philipp D. Kaiser1,
- Bjoern Traenkle1,
- Katharina Kienzle3,
- Stefanie Bunk3,
- Carlotta Struemper3,
- Helene Haeberle3,
- Kristina Schmauder4,5,
- Natalia Ruetalo6,
- Nisar Malek3,7,
- Karina Althaus8,
- Michael Koeppen9,
- Ulrich Rothbauer1,2,
- Juliane S. Walz10,11,12,13,
- Michael Schindler6,
- Michael Bitzer3,7,
- Siri Göpel3,5,* and
- Nicole Schneiderhan-Marra1,*
- 1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
- 2Pharmaceutical Biotechnology, Eberhard Karls University, Tübingen, Germany
- 3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
- 4Institute for Medical Microbiology and Hygiene, University Hospital Tübingen, Tübingen, Germany
- 5German Centre for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
- 6Institute for Medical Virology and Epidemiology, University Hospital Tübingen, Tübingen, Germany
- 7Center for Personalized Medicine, Eberhard Karls University, Tübingen, Germany
- 8Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
- 9Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany
- 10Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany
- 11Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany
- 12Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany
- 13Dr. Margarete Fischer-Bosch-Institute for Clinical Pharmacology and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany
- ↵*denotes shared senior authorship and corresponding authors. Contact Information Nicole Schneiderhan-Marra – Phone number +49 (0)7121 51530 815. Email Address Nicole.schneiderhan{at}nmi.de Postal Address – Markwiesenstrasse 55, 72770 Reutlingen, Germany. Siri Göpel – Phone number +49 (0)7071 29 85415. Email Address siri.goepel{at}med.uni-tuebingen.de Postal Address – Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.
Posted December 06, 2021.
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
